Retatrutide Shows Enhanced Weight Loss in Type 2 Diabetes Patients | Retatrutide News

Retatrutide, a triple agonist from Eli Lilly, is showing promising weight loss results in Type 2 diabetes patients. This development highlights the pote...
Clinical Trials · October 10, 2026